ASH Clinical News

ASH Clinical News is seeking associate editors! Editors have the opportunity to share their views on topics in #hematology, participate in content development, and provide subject matter expertise. For more information and to apply by August 15, visit: ow.ly/OG5050WnYfS.

Using #ctDNA, genetic subtypes of classical #Hodgkin #lymphoma were found to be driven by the mechanism of genetic instability rather than the grouping of #mutations into functional categories, according to new findings published in @BloodPortfolio: ow.ly/ftMb50WrczP

At seven years of follow-up, #daratumumab showed continued single-agent clinical activity in patients with intermediate or high-risk #SmolderingMultipleMyeloma with no new safety concerns, according to the final analysis of the phase II CENTAURUS study: ow.ly/7Bse50WuWbT

Check out what's new in the July issue! Highlights include a feature on the Trump administration's impact on #hematology in its first 100 days, testing and treatment of elevated factor levels post-stroke, recent findings from #ASCO25 and #EHA25, and more: ow.ly/Q9GR50WtAfN

🚨Just published in @ASHClinicalNews: What does moral injury look like in oncology? Not about being tired — but about what it feels like to know what a patient needs and still not be able to give it. This one stayed with me! 🔗: ashpublications.org/ashclinicalnew… #moralinjury #burnout

The #FDA recently approved tafasitamab in combination with #rituximab and #lenalidomide to treat #FollicularLymphoma in adults, based on findings showing a 22.4-month median PFS with the therapy compared with 13.9 months in the control arm: ow.ly/uH9o50Wtk1R

Research published in @haemophilia_jnl reveals that providers may be insufficiently screening — and thus undertreating — iron deficiency in their female patients with bleeding disorders. @ASHClinicalNews summarizes the findings here: ow.ly/LsRC50Ws9oW @ASH_hematology

Editor-in-Chief @AaronGerds, MD, shares highlights from the July issue of @ASHClinicalNews, including a feature on the Trump admins impact on health care and #hematology within its first 100 days and findings from the @ASCO and @EHA_Hematology meetings. ➡️ow.ly/C4qK50WqINT

When used in combination with other medications, #venetoclax appears to be effective in patients with R/R #MultipleMyeloma #MMsm harboring t(11;14), with an ORR of 64%, but is less efficacious when certain other chromosomal abnormalities are also present: ow.ly/BcQU50Wo0Vw

According to findings from #EHA2025, patients with newly diagnosed #MultipleMyeloma #MMsm that was treated with Isa-KRd saw increased levels of sustained MRD negativity compared with patients treated with a combination that did not include #isatuximab: ow.ly/j0cr50WjI2y

According to data from #EHA2025, GLPG5101, a fresh, stem-like, early memory phenotype CD19-directed #CARTcell therapy, demonstrated a manageable safety profile in patients with R/R #nonHodgkin #lymphoma, producing low rates of high-grade toxicities: ow.ly/OY6Y50WlRBk

When compared with the standard assays to assess #ADAMTS13 activity for suspected TTP, newer point-of-care rapid assays demonstrated higher diagnostic accuracy and concordance and lower rates of discrepancies: ow.ly/Eqwz50WktlM #thrombosis #ClottingDisorders #classicalheme

Among patients hospitalized for critical limb #ischemia, individuals with #Myeloproliferative Neoplasms #MPNsm had an increased risk of major adverse #cardiovascular and limb events, especially those with #EssentialThrombocythemia and #myelofibrosis: ow.ly/gvec50WjPan.

Borrowing Health Care: Health care costs continue to be out of budget for many #Americans. A recent Gallup poll found that Americans borrowed a total of $74 billion to pay for #healthcare in the last year, and 58% worry that a major health event would lead to #medical #debt.

ASH Clinical News is seeking associate editors! Editors have the opportunity to share their views on topics in the field, participate in content development, and provide subject matter expertise. For more information and to apply by August 15, visit: ow.ly/pI3G50WjEBR.

Despite pneumococcal conjugate immunization, findings from #EHA2025 reveal that the mortality rate of by #pneumococcal #meningitis remains high for children in France with #SickleCellDisease (SCD), with an observed case-fatality rate of 28%: ow.ly/YXkv50Wgghs

In patients with heavily pretreated R/R #MultipleMyeloma #MMsm, #ciltacel was found to be associated with better treatment responses compared with #idecel but had higher rates of toxicity, such as CRS: ashpublications.org/ashclinicalnew…

See what's to come next month in ASH Clinical News! Highlights of the July issue include a feature article on the #Trump administration's impacts on #healthcare and #hematology in its first 100 days, new findings from #ASCO25 and #EHA2025, and more: ow.ly/uCzR50WfJLY

The 24-hour urine-based response test used for #MultipleMyeloma #MMsm may not be necessary, as data from 600+ patients showed that removing urine assessments from #IMWG response criteria changed response depth assessment for just 1.1% of patients: ow.ly/RUer50Wfwzn

In March, the #FDA approved prophylactic #fitusiran in patients 12 and older with #hemophilia A or B with or without factor VIII or IX inhibitors based on two trials which showed the therapy led to significant reductions in annual #bleeding rates: ow.ly/vrUi50WcUsh